Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.

Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J.

Clinicoecon Outcomes Res. 2017 Feb 27;9:163-172. doi: 10.2147/CEOR.S117650. eCollection 2017.


Cost-Effectiveness of Ipilimumab in Previously Untreated Patients for Advanced Melanoma in Sweden.

Barzey V, Asukai Y, Gueron B, Holmberg C, Kotapati S.

Value Health. 2014 Nov;17(7):A642-3. doi: 10.1016/j.jval.2014.08.2322. Epub 2014 Oct 26. No abstract available.


Patient Count Projections for Advanced Melanoma by Line of Therapy and Other Clinical Characteristics in EU Countries: Results from The UK, Germany, France, Italy and Spain (EU-5).

Gueron B, Kish JK, O'Day K, Martel MJ, Manley Daumont M.

Value Health. 2014 Nov;17(7):A619. doi: 10.1016/j.jval.2014.08.2191. Epub 2014 Oct 26. No abstract available.


Update on asthma control in five European countries: results of a 2008 survey.

Demoly P, Gueron B, Annunziata K, Adamek L, Walters RD.

Eur Respir Rev. 2010 Jun;19(116):150-7. doi: 10.1183/09059180.00002110.


Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire.

Martinez L, Consoli SM, Monnier L, Simon D, Wong O, Yomtov B, Guéron B, Benmedjahed K, Guillemin I, Arnould B.

Health Qual Life Outcomes. 2007 Aug 29;5:53.


Costs of cardiovascular events of diabetic patients in the French hospitals.

Colin X, Lafuma A, Gueron B.

Diabetes Metab. 2007 Sep;33(4):310-3. Epub 2007 Mar 28.


[The cost of complications: implications for the measurement of the cost of type II diabetes mellitus].

Marissal JP, Gueron B, Dervaux B.

Rev Epidemiol Sante Publique. 2006 Apr;54(2):137-47. Review. French.


Supplemental Content

Loading ...
Support Center